160701-58-6

Upstream product

• 245442-82-4 ethyl 3-(tert-butyldimethylsilyloxy)phenyl acetate 
• 22446-38-4 ethyl 3-hydroxyphenylacetate 
• 13398-94-2 2-(3-hydroxyphenyl)ethanol 
• 114774-44-6 (3-{[tert-butyl(dimethyl)silyl]oxy}phenyl)acetic acid 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 160701-51-9 1-(tert-Butyl-dimethyl-silanyloxy)-3-[2-(tert-butyl-dimethyl-silanyloxy)-ethyl]-benzene 

Downstream Products

• 245442-83-5 tert-butyldimethylsilyl 3-(2-hydroxyethyl)-4-iodophenyl ether 
• 295311-79-4 (3-t-butyldimethylsilyloxyphenyl)acetaldehyde 
• 951377-89-2 [(3aS,4E,5S,6aR)-4-ethylidene-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-5-yl]acetic acid 2-[3-(tert-butyldimethylsilyloxy)phenyl]ethyl ester 
• 956964-09-3 C₉H₁₄O₄C₈H₈O 
• 245442-92-6 tert-butyldimethylsilyl 4-iodo-3-(2-iodoethyl)phenyl ether 
• 245442-84-6 tert-butyldimethylsilyl 4-iodo-3-(2-mesyloxyethyl)phenyl ether 
• 245442-93-7 benzyl 2-[5-(tert-butyldimethylsilyl)-2-iodophenyl]ethyl selenide 

Relevant academic research and scientific papers

NOVEL PHENYL-ISOXAZOL-3-OL DERIVATIVE

The present invention relates to a compound represented by formula (I), which has a GPR120 agonist action and thus is useful for treatment of diabetes mellitus or hyperlipidemia, or a pharmaceutically acceptable salt thereof. In the formula, (AA) represents a phenyl or the like, which may be substituted with a lower alkoxy group or the like; (BB) represents a divalent group or the like, derived by removal of two hydrogen atoms from a benzene which may be substituted with a halogen atom or the like; X represents a spacer having a main chain composed of 1-8 carbon atoms wherein 1-3 carbon atoms in the main chain may be substituted with an oxygen atom or the like; and Y represents a hydrogen atom or the like.

Purine derivatives

This invention relates to compounds of the general formula: in which RA, RB, RC and RD are as defined herein, and to their preparation and use.

Toward Novel Antioxidants: Preparation of Dihydrotellurophenes and Selenophenes by Alkyltelluride-Mediated Tandem SRN1/SHi Reactions

Reaction of 1-(2-iodophenyl)-1-methyloxirane (12) with 2 equiv of sodium n-butyltellurolate (n-BuTeNa), generated by the sodium borohydride reduction of di-n-butyl ditelluride, in THF, affords 2,3-dihydro-3-hydroxy-3-methylbenzo[b]tellurophene (13) in 62% yield, together with a small quantity of 1-(n-butyltelluro)-2-phenyl-2-propanol (27). This transformation presumably involves a tandem SRN1/SHi sequence. Similar reactions of 1-(benzylseleno)-2-phenyl-2-propanol (5a, R = Me) and 1-allyloxy-2-iodobenzene (15) afforded 2,3-dihydro-3-hydroxy-3-methylbenzo[b]selenophene (17, 74%), and 3-(n-butyltelluro)methyl-2,3-dihydrobenzo[b]furan (18, 50%), respectively. Lithium alkyltellurolates, generated by direct tellurium insertion into the required alkyllithium, or sec-butyl or tert-butyl substitution on tellurium provide product distributions similar to those observed for reactions involving n-BuTeNa. Lithium or sodium phenyltellurolate returned only starting materials from these reaction mixtures. The 2-[2-(n-butyltelluro)-1-hydroxy-1-methyl]ethylphenyl radical (14) is estimated to cyclize with kc 5 × 108 s-1 at 25 °C. The tandem SRN1/SHi sequence has been applied to the preparation of the antioxidant analogues, 5-hydroxy-2,3-dihydrobenzo[b]- tellurophene and selenophene (31, 32).

Selective removal of phenolic and alcoholic silyl ethers

Potassium carbonate/Kriptofix 222 and pyridinium p-toluenesulfonate or BF3-etherate have been found to remove the tert-butyldimethylsilyl group from phenolic and alcoholic silyl ethers, respectively. This methodology should find wide applicability in complex organic synthesis.